ARTICLE | Clinical News
FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine
September 21, 2018 5:36 PM UTC
FDA approved Ajovy fremanezumab-vfrm from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) on Sept. 14 to prevent migraine in adults. The mAb targeting the calcitonin gene-related peptide ligand is the second in its class approved in the indication.
Teva said it expects monthly and quarterly injectable doses of Ajovy to be available within a week at a wholesale acquisition cost (WAC) of $575 and $1,725, respectively...
BCIQ Company Profiles
BCIQ Target Profiles